mGlu2 NAM for mild neurocognitive disorders

mGlu2 NAM for the treatment of mild neurocognitive disorders, or mNCD.

We are developing mGlu2 NAM as a novel orally available treatment for mNCD associated with Alzheimer’s disease, Parkinson’s disease and depressive disorders. The program is in late lead optimization phase and we expect to enter clinical candidate selection phase early in 2022.